BRCA2 and ovarian carcinoma: The use of PARP (poly ADP ribose polymerase) inhibitor drugs for treating breast cancers or ovarian cancers with BRCA1/BRCA2 mutations is a widely documented example where synthetic lethality is used for effective treatment of cases with driver alterations [6,22].